Abstract
Countries worldwide have adopted various strategies to minimize the socio-economic impact of the ongoing COVID-19 pandemic. Stringency and efficacy of imposed measures vary due to diversity of organizational cultures and ingrained societal practices, but also universally reflect the standpoint from which protecting public health and saving economy are seen as contradictory objectives. We analyzed cumulative deaths per capita and cumulative mobility reduction related to the decrease of economic activity in terms of Pareto optimality to show that as long as epidemic suppression is the aim, the trade-off between the death toll and economic loss is illusory: high death toll correlates with deep lockdown and thus, very likely, with severe economic downturn. We explained this effect by analyzing national epidemic trajectories in the mobility reduction vs. reproduction number (R) plane. When the number of daily new infections is high, mobility reduction is the only way to bring R below 1, but when new infections become sporadic, the epidemic can be suppressed by efficient testing complemented by relatively mild restrictions. South American trajectories suggest that lifting mobility restrictions at R > 1 may ultimately lead to the “herd immunity scenario”, in which transient lockdown only adds economic costs to an inevitably high death toll.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Science Centre (Poland) grant 2018/29/B/NZ2/00668.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
(N/A)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available within the article.